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Abstract
The pathogenesis of HIV-associated neurocognitive impairment (NCI) may involve iron dysregulation. In 243 HIV-seropositive
adults without severe comorbidities, we therefore genotyped 250 variants in 20 iron-related genes and evaluated their associations
with magnetic resonance imaging measures of brain structure and metabolites, including measures previously linked to NCI.
Multivariable regression analyses examined associations between genetic variants and neuroimagingmeasures, adjusting for relevant
covariates and multiple testing. Exploratory analyses stratified by NCI (Global Deficit Score ≥ 0.5 vs. <0.5), virus detectability in
plasma, and comorbidity levels were also performed. Of 27 variants (in 12 iron-regulatory genes) associated with neuroimaging
measures after correction for the 37 haplotype blocks represented, 3 variants survived additional correction for the 21 neuroimaging
measures evaluated and demonstrated biologically plausible associations. SLC11A1 rs7576974_Twas significantly associated with
higher frontal gray matter N-acetylaspartate (p = 3.62e−5). Among individuals with detectable plasma virus, TFRC rs17091382_A
was associated with smaller subcortical gray matter volume (p = 3.23e−5), and CP rs4974389_A (p = 3.52e−5) was associated with
higher basal ganglia Choline in persons with mild comorbidities. Two other strong associations were observed for variants in
SLC40A1 and ACO2 but were not robust due to low minor-allele frequencies in the study sample. Variants in iron metabolism
and transport genes are associated with structural and metabolite neuroimaging measures in HIV-seropositive adults, regardless of
virus suppression on antiretroviral therapy. These variants may confer susceptibility to HIV-related brain injury and NCI. Further
studies are needed to determine the specificity of these findings to HIV infection and explore potential underlying mechanisms.
Keywords Iron-regulatory gene .Brain . StructuralMRI .Magnetic resonance spectroscopy (MRS) .HIV .Association studies in
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Introduction
Despite effective antiretroviral therapy (ART), HIV-associated
neurocognitive impairment (NCI) remains common in HIV-
seropositive (HIV+) individuals and is rising in prevalence
(Heaton et al. 2015; Sheppard et al. 2015). Recent studies
suggest that brain alterations occur even during successful
ART and at early stages of infection and are associated with
NCI (Harezlak et al. 2011; Cysique et al. 2018; Fennema-
Notestine et al. 2013; Valcour et al. 2012; Alakkas et al.
2019). The pathogenesis of NCI is incompletely understood,
and host genetics is likely to play a role in individual suscep-
tibility (Kallianpur and Levine 2014; Levine et al. 2014).
Variants in iron-regulatory genes are associated with brain
integrity and healthy aging (Gebril et al. 2011; Jahanshad
et al. 2012). Dysregulation of iron in the brain is observed in
neurodegenerative disorders, although its precise role in path-
ogenesis remains unclear (Hadzhieva et al. 2014). The
APOE-ε4 allele, an established risk factor for Alzheimer’s
disease, has been linked to the iron-transport protein ferritin
within the CNS (Chang et al. 2014; Ayton et al. 2015), and
recent studies support a link between APOE-ε4 and NCI in
HIV+ persons older than 60 years (Spector et al. 2010; Panos
et al. 2013; Wendelken et al. 2016). Further studies of the role
that genetics of host iron metabolism may play in promoting
brain changes are needed in the ART era, amidst milder clin-
ical phenotypes, and accounting for potential confounding
factors. Neuroimaging endophenotypes in HIV may be more
powerful outcomes for the identification of host genetic risk
factors than direct measures of cognitive function, a complex
phenotype which can fluctuate over short periods of time
(Kallianpur and Levine 2014).
The aim of this study was to determine associations be-
tween neuroimaging measures and common variants in iron-
related genes in the context of HIV infection, focusing on
genes critical to iron transport and cellular and/or mitochon-
drial iron metabolism. The study was conducted in 243 HIV+
adults without current substance use disorder or severe
(confounding) comorbid conditions, who had comprehensive
neurocognitive phenotyping. Stratified analyses were also per-
formed to detect associations specific to important HIV+ pop-
ulation subsets in the ARTera, such as those with undetectable
plasma viral load.
Methods
Study participants
Study participants included 243 HIV+ volunteers from the
CNS HIV Anti-Retroviral Therapy Effects Research
(CHARTER) observational study (Heaton et al. 2015), who
had participated in CHARTER genetic studies and in a
multicenter, prospective MRI study, as previously described
(Anderson et al. 2015; Fennema-Notestine et al. 2013;
Jernigan et al. 2011). Individuals with severe (confounding)
comorbidities that were deemed by clinical neurologists to
prevent accurate diagnosis of HIV-associated NCI were ex-
cluded, as discussed below. Recruitment and scanning of
CHARTER study participants conformed to standardized pro-
tocols and took place at five U.S. sites: Johns Hopkins
University (Baltimore, Maryland, n = 37); the Icahn School
of Medicine of Mount Sinai (New York, New York, n = 55);
the University of California at San Diego (San Diego,
California, n = 70); the University of Texas Medical Branch
(Galveston, Texas, n = 55); and the University of Washington
(Seattle, Washington, n = 26). All procedures were approved
by the Human Subjects Protection Committees of each partic-
ipating institution, and written informed consent was obtained
from all study participants.
Neurocognitive and psychiatric assessments
All CHARTER study participants underwent structured inter-
views, physical and neurological examinations, and compre-
hensive neurocognitive assessments, including 15 measures
spanning 7 cognitive domains commonly impacted by HIV
infection (Heaton et al. 2010; Heaton et al. 2011). Composite
test scores (Global Deficit Score, or GDS) were derived from
demographically corrected and standardized scores (T-scores)
on individual test measures. NCI was defined either by a di-
chotomous GDS-based variable (GDS ≥ 0.5, indicating global
NCI, and GDS < 0.5, considered neurocognitively unim-
paired), or by well-accepted Frascati criteria for the diagnosis
of HIV-associated neurocognitive disorder, which also incor-
porates assessment of (self)-reported functional impairment
by the study participant or caregivers (Heaton et al. 2010;
Heaton et al. 2011; Antinori et al. 2007). Based on a published
algorithm, the presence and severity of HIV-associated
neurocognitive disorder was defined by 1) the presence of
impairment in at least two of seven ability domains assessed
by the test battery, 2) the absence of severe (confounding)
neuro-medical conditions (comorbidities), which preclude a
diagnosis of NCI (e.g., ongoing substance abuse, prior stroke
or cardiovascular complications without return to normal cog-
nition after the event (Heaton et al. 2010)), and 3) assessment
of functional impairment by self-report combined with
performance-based criteria (Heaton et al. 2011; Antinori
et al. 2007). Allowable comorbidities were chronic stable con-
ditions deemed by experts in neurology/psychiatry to be “min-
imal in severity (or incidental to NCI)” or “mild-to-moderate
(contributing to NCI)”. We excluded individuals with “se-
vere” (confounding) comorbid conditions that could fully ex-
plain impairment, thereby making contribution from HIV in-
fection difficult to infer (Heaton et al. 2010); our recent work
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supports worse brain integrity in this confounded category
(Saloner et al. 2019).
Psychiatric diagnoses were determined using the
computer-assisted Composite International Diagnostic
Interview, a structured instrument widely used in psychiatric
research. This tool classifies current and lifetime diagnoses of
mood disorders and substance use disorders as well as other
mental disorders. Current mood was also evaluated using the
Beck Depression Inventory-II (Heaton et al. 2011).
Medical assessments
Medical history was gathered, structured medical and neurolog-
ical examinations were performed, and blood, urine, and CSF
(for those who consented to lumbar puncture) samples were
collected at initial and follow-up visits. The following clinical
parameters were evaluated using structured interviews and lab-
oratory assessments, as appropriate: use of ART/history of ART
use (including past exposure to older, more neurotoxic
dideoxynucleoside reverse-transcriptase inhibitors, so-called
“d-drugs”), detectability of HIV RNA and viral load in plasma,
cluster designation (CD) 4+ T cell nadir, current CD4+ T cell
count, and serologic evidence of hepatitis C virus infection, a
common comorbidity that can affect the CNS (Fletcher and
McKeating 2012). Plasma and CSF viral loads were quantified
by reverse-transcriptase-PCR ultrasensitive assay (nominal low-
er quantitation limit 50 copies/mL). Nadir CD4+ T cell count
was based on a combination of self-report and medical records.
Current CD4+ T cell counts were measured by flow cytometry.
Neuroimaging assessments
All MRI was performed on six General Electric 1.5-Tesla
scanners annually reviewed for quality at five sites; because
scanner differences (e.g., hardware, software, head coil up-
grades) can influence neuroimaging metrics, we included a
“scanner” variable in statistical analyses to account for
scanner-related effects between sites (Fennema-Notestine
et al. 2007). Four series were acquired for structural morpho-
metric analysis, including coronal two-dimensional T2- and
proton-density (PD)-weighted fast spin echo sequences (sec-
tion thickness = 2.0 mm), and three-dimensional sagittal T1-
and PD-weighted spoiled gradient recalled acquisitions (sec-
tion thickness = 1.3 mm) (Fennema-Notestine et al. 2013;
Jernigan et al. 2011). Magnetic resonance spectroscopy
(MRS) was performed using a standardized point-resolved
spectroscopy protocol (echo time = 35 ms, repetition time =
3000 ms) (Anderson et al. 2015).
Multi-channel structural MRI As described previously
(Fennema-Notestine et al. 2013; Jernigan et al. 2011), we used
the multi-channel dataset in a semi-automated workflow to
measure cortical, subcortical, and cerebellar gray matter;
cerebellar, cerebral and abnormal (e.g., hyperintense regions
on T2-weighted images) white matter; and ventricular, cere-
bral sulcal, and cerebellar cerebrospinal fluid, as well as supra-
and infra-tentorial cranial vault volumes to account for indi-
vidual differences in head size. The workflow includes image
inspection for motion and other artifacts, re-slicing to a stan-
dard space, intra-subject mutual information registration, bias-
correction with nonparametric non-uniformity normalization,
removal of non-brain tissue, three-tissue segmentation (gray
matter, white matter, and CSF), abnormal white matter desig-
nation, and anatomical labeling performed by trained anato-
mists. This approach includes the identification of regions of
cerebral white matter with abnormal MRI signal characteris-
tics; these regions segmented as gray matter, but are anatom-
ically located within the white matter.
Single-voxel MRS As described previously (Anderson et al.
2015), three regional voxels were acquired: frontal graymatter
(20x20x20mm and 64 acquisitions), frontal white matter
(20x20x20mm and 64 acquisitions), and basal ganglia
(20x20x15mm and 96 acquisitions). MRS concentrations of
N-acetylaspartate, Choline, Myo-inositol, and Creatine were
quantified using LCModel with water suppression
(Provencher 2001). Water suppression allows for the exami-
nation of absolute metabolite levels, our primary measures of
interest; although ratios to Creatine have been commonly re-
ported with the aim to provide standardization across sites and
studies, this approach has limitations and there is evidence that
HIV infection independently affects Creatine levels directly,
confounding the interpretation of ratio values and existing
findings (as in Jansen et al. 2006; Anderson et al. 2015).
Only metabolite estimates for appropriately placed voxels
with adequate spectra (standard deviation<21) were used;
therefore, sample size varied by MRS region or metabolite.
Structural segmentation was used to estimate the proportion of
relevant tissue volume within each MRS voxel (e.g., amount
of gray matter in frontal gray matter voxel) to control for
individual sampling variability.
Gene selection and genotyping
We selected 20 iron-related genes for analysis, listed in
Table 1, which are known to contain common variants (i.e.,
minor-allele frequency ≥ 1% in a population) and are involved
in one or more of the following: (a) nuclear iron storage and
transport, (b) the ferroportin-hepcidin pathway, (c) mitochon-
drial iron transport, and/or (d) neurodegenerative phenotypes
or neuronal differentiation in humans in the published litera-
ture. This gene list was not intended to be exhaustive and
included only the major genes associated with iron regulation
in humans, most of which have been relatively well character-
ized in animal or invertebrate models. We evaluated 250
single-nucleotide polymorphisms (SNPs) at these iron-
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related genetic loci of interest for which genotype data were
available for CHARTER cases. Most of the SNPs evaluated in
this study were very common (20–40%). Genomic DNA had
previously been isolated and subjected to whole-genome
genotyping using the Affymetrix™ Human SNP Array 6.0
platform, as published elsewhere (Kallianpur et al. 2014).
Quality control of genetic data Importantly, only genotypes at
the selected iron-related loci, obtained from the Affymetrix
array, were analyzed. However, standard quality control
(QC) of genome-wide data was previously performed in all
CHARTER genetics study participants and included the fol-
lowing steps: 1) checks for duplicates, known related
individuals, and cryptic relatedness of individuals (identity-
by-descent method, using a PI_HAT cut-off <0.2 to confirm
non-relatedness); 2) tests of Hardy-Weinberg equilibrium (ex-
cluded SNPs had p values <1e-6); 3) checks of genetic sex;
and 4) determinations of missingness (per individual and per
SNP). A total of 862,089 SNPs remained following QC, in-
cluding the iron-related SNPs that then were specifically se-
lected for use in the present study. Population stratification
was assessed by multidimensional scaling analysis of the N
x N matrix of genome-wide, identity-by-state pairwise dis-
tances. SNPs with a minor allele frequency (MAF) <1%
(11,745 SNPs) were excluded. The genotyping success rate
overall was 99.7% in the cleaned (post-QC) dataset.
Table 1 Selected genes involved in iron metabolism, regulation, and/or transport evaluated in this study
Gene (protein) Locus Function and/or relevance to the CNS
HFE (hemochromatosis) 6p21.3 Regulation of iron stores and hepcidin synthesis; common SNPs linked to genetic iron
overload (hemochromatosis) and HIV sensory neuropathy
HFE2 (hemojuvelin, HJV) 1q21.1 Regulation of hepcidin synthesis; SNPs linked to genetic hemochromatosis
SLC40A1 (ferroportin) 2q32.2 Major regulator of macrophage iron export; immune defense
HAMP (hepcidin) 19q13.12 Master regulator of gut iron absorption and macrophage ferroportin levels (macrophage
iron export)
BMP2
(bone morphogenetic protein 2)
20p12.3 Controls ferritin levels, hepcidin synthesis; neural differentiation
BMP6
(bone morphogenetic protein 6)
6p24–23 Ligand for HJV, HFE; regulates hepcidin synthesis
TF (transferrin) 3q22.1 Major cellular iron transporter in blood and brain
TFRC (transferrin receptor 1) 3q29 Receptor for transferrin, major cellular iron transport and uptake protein; hepatic
iron-sensing; regulation of hepcidin and mitochondrial fusion/function
TFR2 (transferrin receptor 2) 7q22.1 Alternative transferrin receptor which mediates transferrin-bound iron uptake (and iron
loading) by the liver regardless of tissue iron status; mutated in hemochromatosis type 3
SLC11A1 (natural resistance-associated
macrophage protein 1, NRAMP1)
2q35 Transport of iron out of endosomes, white blood cell function
SLC11A2 (divalent metal transporter 1) 12q13.12 Encodes metal binding protein, participates in cellular iron absorption in gut; mutations
result in anemia, iron overload and inflammation
CP (ceruloplasmin) 3q24-q25 Circulating plasma copper ferroxidase (Fe2 +➔Fe3+) and iron-binding protein; homo-
logue of hephaestin; important in glial cell iron homeostasis and neuronal survival in the
CNS; mutations cause cerebellar ataxia, iron loading
B2M (beta-2-microglobulin) 15q21.1 Serum iron-binding protein and intracellular stabilizer of Hfe protein; positive acute-phase
protein; involved in immune function
ATP13A2 (ATPase iron transporter) 1p36.13 Important in mitochondrial energy metabolism, resistance to toxin-induced apoptosis; mu-
tations cause hereditary parkinsonism with dementia
FTH1 (ferritin heavy chain) 11q12.3 Ferritin subunit with ferroxidase activity, stores iron, binds Tfr1; delivers iron to
oligodendrocytes
ACO1 (cytoplasmic aconitase) 9p21.1 Cytoplasmic iron-sulfur-cluster protein (iron-dependent aconitase); links cellular iron
sensing to Tfr and ferritin synthesis and to the tricarboxylic acid cycle
ACO2 (mitochondrial aconitase) 22q13.2 Mitochondrial counterpart of ACO1, may be essential for mtDNA maintenance and
mitochondrial iron homeostasis; interacts with FXN gene product, frataxin
HEPH (hephaestin) Xq12 Membrane-bound ferroxidase and ceruloplasmin homologue; required for transmembrane
iron transport (Fe2 +➔Fe3+)
FXN (frataxin) 9q21.11 Mitochondrial iron transporter, delivers iron to ferrochelatase (rate-limiting step in heme
synthesis)
FTMT (mitochondrial ferritin) 5q23.1 Mitochondrial iron storage molecule, regulates balance of iron between mitochondria and
cytosol
Abbreviations: Tfr, transferrin receptor (1) protein; SNP, single-nucleotide polymorphism; CNS, central nervous system; Fe, iron
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Statistical analyses
Since assumptions of normality for both Kolmogorov-
Smirnoff and Shapiro-Wilk tests were violated for several
neuroimaging variables, all measures were log-transformed
prior to analyses, and the Kolmogorov-Smirnoff test was re-
applied to confirm normality. The effects of numerous covar-
iates were regressed from all neuroimaging measures to deter-
mine the need to adjust for these potentially confounding var-
iables in multivariable regression models: covariates evaluat-
ed for inclusion were scanner, age, sex, genetic ancestry (prin-
cipal components from genome-wide genetic data), education
(years), Wide-Range Achievement Test score (an estimate of
reading ability), nadir CD4+ T cell count, HIV RNA detect-
ability in plasma (yes/no), ART (on vs. off), hepatitis C virus
serostatus, history of d-drug use, current substance use (yes/
no), estimated duration of HIV infection (months), history of
diabetes mellitus (yes/no), current or lifetime history of a ma-
jor depressive disorder, current or lifetime history of alcohol
abuse, and comorbidity (minimal vs. mild-to-moderate and
contributory to NCI). Because scanner differences (e.g., hard-
ware, software, head coil upgrades) influence neuroimaging
metrics, we included a “scanner” variable (six levels, one for
each scanner at five sites, one site having two scanners) in
statistical analyses to account for scanner-related differences
between study sites (Fennema-Notestine et al. 2007).
A generalized linear model multivariable analysis of co-
variance (MANCOVA) was used to evaluate associations be-
tween continuous (log-transformed) neuroimaging measures
and genotype at each locus using PLINK and unbiased, addi-
tive allelic models. Corresponding relevant neuroimaging co-
variates were included in all uni- and multi-variable regression
models of neuroimaging outcomes: 1) for MRS, the propor-
tion of relevant tissue volume within each voxel (e.g., amount
of gray matter in frontal gray matter) to control for individual
variability, thereby improving sensitivity for detection of ge-
netic effects (Anderson et al. 2015), and 2) for structural MRI,
either supra- (for cerebral measures) or infra- (for cerebellar
measures) tentorial vault size to account for variation associ-
ated with individual differences in head size (Jernigan et al.
2011). Due to adjustment for cranial vault size in all models,
we did not additionally adjust for sex.
All regression models were adjusted for age, nadir CD4+ T
cell count, the first three ancestry principal components, scan-
ner, and plasma HIV RNA detectability, as well as for specific
covariates that were found to be significantly associated
(p < 0.05) with individual neuroimaging measures in univariate
analyses (Online Resource Tables ESM-1 and ESM-2).
Analyses of frontal white matter N-acetylaspartate and
Choline, basal ganglia N-acetylaspartate and Creatine, total
white matter, sulcal CSF, and cerebellar white matter and gray
matter included only the covariates mentioned. Sincemost peo-
ple with HIV infection and access to ART have asymptomatic
NCI or are cognitively unimpaired, and the etiology of NCI is
most perplexing among relatively healthy individuals with sup-
pressed viremia, we also tested the hypotheses that iron-related
genes modulate the risk of NCI in these subsets. Analyses were
therefore stratified by 1) plasma HIV RNA detectability (in
which case models in the subgroup with detectable HIV
RNAwere adjusted for HIVRNA load), 2) presence or absence
of NCI (GDS ≥0.5 or < 0.5, respectively), and 3) comorbidity
level (absent/minimal vs. mild-to-moderate). All statistical
analyses were conducted using either SAS or R software.
The linkage disequilibrium structure and number of haplo-
type blocks (effective independent statistical tests per genomic
region) were determined using Haploview: the 250 selected
SNPs fell into 37 haplotype blocks. Two levels of correction
for multiple testing were therefore applied: 1) correction for
the 37 haplotype blocks analyzed (significance level
p < 0.00135), and 2) additional correction for 21 neuroimag-
ing measures evaluated (significance level p < 6.43e-5).
Bonferroni corrections were not deemed appropriate due to
the known interdependence and coordinated regulation of
many iron-related genes (Hentze et al. 2010; Kuhn 2015).
We estimated a priori that the proposed study of 250 indi-
viduals with available data would have 80% power to detect an
additive genetic association model explaining 2.5% of the var-
iance in a neuroimaging measure at an uncorrected p value
<0.05 (or 3.2% of the variance at an overly conservative,
Bonferroni-corrected p value <0.00014), assuming 350 SNP
tests. Based on evidence from the Alzheimer’s disease neuro-
imaging genetics literature, for disease-associated genes with
small odds ratios (1.15 or less), we predicted the ability to
detect effect sizes accounting for approximately 5% of the var-
iance in a disease-related quantitative neuroimaging measure.
Results
Baseline characteristics of study participants across all neuro-
imaging measures, and among neurocognitively impaired and
unimpaired individuals, are presented in Table 2. The mean age
of the group was 44 years, and 81% were male. Self-reported
race/ethnicity was 43.6% non-Hispanic white, 44.4% black,
10.3% Hispanic, and 1.6% “other”. Approximately 77% of
individuals were receiving ART at the time of neurocognitive
assessment and neuroimaging, and 54% had a history of d-drug
exposure; mean estimated duration of HIV infection was
132 months. HIV RNA was detectable in plasma in 49%.
Comorbidities were deemed mild-to-moderate (and contributo-
ry to NCI) in 31%. A few individuals (3.3%) reported current
substance dependency or abuse, and 53% had a lifetime history
of an alcohol dependency or abuse disorder. A history of a
major depressive disorder was present in 53%, and approxi-
mately 10% had a documented diagnosis of diabetes mellitus.
Associations between demographic and clinical characteristics
Brain Imaging and Behavior
for MRS (Online Resource Table ESM-1) and structural MRI
volumes (Online Resource Table ESM-2) are provided in sup-
plemental materials.
Results of neuroimaging-genotype analyses in the entire
CHARTER study population, as well as stratified analyses,
are summarized in Fig. 1. Twenty-seven SNPs in 12 of the
genes evaluated were significantly associated with one or
more structural and/or metabolic neuroimaging measures in
multivariable-adjusted analyses after applying the correction
for the 37 haplotype blocks represented (p < 0.00135). Eight
of these associations were observed in analyses that included
all 243 study participants (Table 3). SNP rs7576974 (T allele)
in the SLC11A1 gene was associated with higher frontal gray
matter N-acetylaspartate, and this association remained signif-
icant after applying both levels of multiple-testing correction
(p < 6.43e−5); SNP rs13358715_T in FTMT was associated
with lower frontal gray matter N-acetylaspartate (p =
0.0011). Higher cortical gray matter volume was associated
with ACO1 SNP rs2026739_G (p = 0.0012) and FXN SNP
rs11145403_G (p = 8.95e−4). BMP6 SNP rs9505293_T was
associated with lower cerebellar gray matter volume (p =
4.92e−4) and FXN SNP rs11145043_G with higher sulcal
CSF volume (p = 6.87e−4). Two SNPs, BMP6 rs7454156_G
and ACO1 rs16918276_T, were associated with higher basal
ganglia Creatine (p = 7.33e−4 and 2.94e−4, respectively).
Stratified analyses in subsets of individuals based on HIV
RNA detectability in plasma, presence of NCI, and severity of
comorbid conditions (minimal, or incidental to NCI vs.
mild/moderate, or contributing to NCI), were also performed
(Fig. 1 and Table 4). Analyses stratified by plasma virus de-
tectability yielded five SNP associations in three genes
(SLC40A1, BMP6, and FTMT) among 119 individuals with
undetectable virus and 3 significant SNP associations span-
ning three genes (TFRC, BMP6, and FXN) in those with de-
tectable viremia (n = 117). Among individuals with NCI (n =
76), six SNPs in four genes (ACO1, BMP6, FXN, and TF)
Table 2 Demographic and HIV disease characteristics stratified by presence of neurocognitive impairment (NCI)
GDS-Defined neurocognitive impairment
Not Impaired (N = 167) Impaired (N = 76)
Age (years) 43.2 (8.0) 46.1 (7.1)
Education (years) 12.7 (2.3) 13.6 (2.4)
Sex (% Women) 28 (16.8%) 18 (23.7%)
Estimated Duration of HIV Infection (months) 126 (60,184) 165 (66,198)
Race/Ethnicity
(Self-reported)
White 71 (43%) 35 (46%)
Black 81 (48%) 27 (35%)
Hispanic 13 (8%) 12 (16%)
Other 2 (1%) 2 (3%)
Nadir CD4+ T Cell Count (× 103/mm3) 150 (36, 300) 135 (18, 265)
Log10 (HIV RNA) in Plasma (Copies/mL) 1.76 (1.70, 4.01) 1.70 (1.70, 3.44)
HIV RNA Undetectable in Plasmaa 80 (49%) 39 (53%)
Currently on ARTb 121 (74%) 61 (82%)
D-Drug Use No D-drug use 75 (46%) 31 (42%)
Past use 71 (44%) 33 (45%)
Currently on 17 (10%) 10 (14%)
HCV Serostatus (% Positive) 45 (27%) 16 (21%)
Diabetes Dx 15 (9%) 9 (12%)
LT MDD (% Yes) 95 (57%) 35 (46%)
LTAlcohol Use Dx 96 (57%) 35 (46%)
Current Substance Use Dx 4 (2%) 4 (5%)
WRAT 98 (90, 107) 95 (82, 102)
Comorbidity Mild-to-moderate 42 (25%) 33 (43%)
Absent/Minimal 125 (75%) 43 (57%)
Values shown are the mean (SD), median (IQR), or count (percentage). Abbreviations: GDS, global deficit score; SD, standard deviation; IQR, interquartile
range; WRAT, wide-range achievement test (measure of reading comprehension); LLQ, lower limit of quantitation (of assay); HCV, hepatitis C virus
seropositivity; ART, antiretroviral therapy;D-drug, dideoxynucleoside analog drug; LTMDD, lifetime history of a major depressive disorder;Dx, diagnosis
of alcohol or other substance use diagnoses encompass diagnoses of current or lifetime (mostly remote) history of abuse or dependency disorder
a 3 impaired and 4 unimpaired persons did not have this data available
b 2 impaired and 4 unimpaired persons did not have this data available
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were statistically significant; among 167 neurocognitively
normal individuals, eight SNP associations in five genes
(ACO1, BMP6, HEPH, HFE, and SLC11A1) were detected.
Stratification by comorbidity level (absent/minimal vs. mild-to-
moderate) yielded four significant SNPs in four genes (ACO2,
BMP6,CP, and TF) in individualswithmild-to-moderate comor-
bidities and a single SNP in BMP6 in the subgroup with absent/
minimal comorbid conditions. Minor allele frequencies of sig-
nificantly associated variants ranged from 0.014 to 0.461.
Adjusted beta coefficients from multivariable regression models
and odds ratios for the coded alleles using a dominant genetic
model are presented in Online Resource Table ESM-3 for
statistically significant SNPs that survived both levels of correc-
tion. Of note, alleles rs13404407_C in SLC40A1 (ferroportin)
and rs9611598_A in ACO2 (mitochondrial aconitase) were pres-
ent at less than 5% frequency in the study sample.
Discussion
To our knowledge, this study represents the first to associate
genes involved in ironmetabolism, transport and/or regulation
with neuroimaging measures in the context of HIV infection,
and one of very few studies examining these associations in
Fig. 1 Summary of Iron-related genes in which SNPs were significantly
associated with neuroimaging measures after corrections for multiple
statistical tests. Abbreviations: SNPs, single-nucleotide polymorphisms;
FXN, frataxin; TFRC, transferrin receptor 1; TF, transferrin; SLC11A1,
natural resistance-associated macrophage protein 1; BMP6, bone
morphogenetic protein 6; FTMT, mitochondrial ferritin; SLC40A1,
ferroportin; HEPH, hephaestin; HFE, hemochromatosis (1) gene; CP,
ceruloplasmin; ACO1, cytoplasmic aconitase; ACO2, mitochondrial
aconitase; CP, ceruloplasmin; TF, transferrin
Table 3 Multivariable-adjusted SNP associations with neuroimaging measures in all 243 HIV+ study participants
Gene SNP (coded allele) Type of variant # Neuroimaging measures
nominally associated (p < 0.05)
Neuroimaging measure(s) Direction of effect p value MAF
SLC11A1 rs7576974 (T) Intronic/5’UTR 8 Frontal GM - NAA Higher 3.62e-5 0.066
BMP6 rs9505293 (T) Intronic 23 Cerebellar GM Lower 4.92e-4 0.138
rs7454156 (G) Intronic 15 BG - Cr Higher 7.33e-4 0.175
ACO1 rs2026739 (G) Intronic 13 Cortical GM Higher 1.16e-3 0.339
rs16918276 (T) Intronic 20 BG - Cr Higher 2.94e-4 0.109
FXN rs2498434 (G) Intronic 16 Sulcal CSF Higher 6.87e-4 0.495
rs11145043 (G) Intronic/3’UTR 9 Cortical GM Higher 8.95e-4 0.366
FTMT rs13358715 (T) Intronic 10 Frontal GM - NAA Lower 1.07e-3 0.054
All associations that survived the first level of multiple-testing correction for number of haplotype blocks evaluated (p < 0.00135) are shown; the single
SNP that survived both levels of correction (for 37 haplotype blocks and 21 neuroimaging measures, p < 6.43e-5) is shown in bold
Abbreviations: GM, gray matter;WM, white matter; BG, basal ganglia; Cr, creatine; CSF, cerebrospinal fluid;NAA,N-acetylaspartate; SLC11A1, natural
resistance-associated macrophage protein 1; BMP6, bone-morphogenetic protein 6, ACO1, cytoplasmic aconitase; FXN, frataxin; FTMT, mitochondrial
ferritin; OR, odds ratio; MAF, minor allele frequency
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humans more broadly. Although iron dysregulation has been
consistently linked to neurodegenerative disorders, few stud-
ies have investigated the contribution of variation in iron-
related genes to metabolic or structural brain characteristics
(Gebril et al. 2011; Jahanshad et al. 2012; Gazzina et al.
2016). Furthermore, five SNP associations that we observed
in this diverse population of HIV+ individuals remained sig-
nificant following p value adjustment for multiple statistical
tests, including adjustment for the number of distinct haplo-
types and neuroimaging measures that were evaluated.
One of these SNPs, rs7576974_T, is located in SLC11A1, a
gene which is responsible for macrophage-monocyte iron
recycling and encodes a key macrophage antimicrobial resis-
tance protein, also known as Nramp1. This SNPwas associated
with higher frontal gray matter N-acetylaspartate among all
study participants, as well as within the unimpaired subset.
Other SNPs in this gene are known to be associated with either
increased or decreased risk of autoimmune and infectious dis-
orders, and a nearby SNP in SLC11A1 was linked to reduced
autoimmune inflammation (Archer et al. 2015). Given that N-
acetylaspartate is a marker of neuronal integrity and is lower in
the setting of HIV infection (Harezlak et al. 2011; Cysique et al.
2018), we postulate that this SNP is neuroprotective in HIV+
persons. SLC11A1 genotypes have been linked to mortality in
Table 4 Summary of multivariable-adjusted SNP associations with neuroimaging measures in analyses stratified by plasma HIV RNA detectability,
comorbidity (mild-to-moderate vs. absent/minimal), and presence of GDS-defined neurocognitive impairment
Study stratum Gene SNP (coded allele) Type of variant Neuroimaging measure(s) p-value MAF
Undetectable Plasma HIV RNA (n = 119) SLC40A1 rs13404407 (C) Intronic Abnormal WM 2.23e-6 0.029
BMP6 rs11243204 (G) Intronic Sulcal CSF 8.81e-5 0.158
BMP6 rs11760020 (T) Intronic Sulcal CSF 4.37e-4 0.249
BMP6 rs267807 (A) Intronic Subcortical GM 1.11e-3 0.395
FTMT rs13358715 (T) Intronic Frontal WM - NAA 1.24e-3 0.054
Detectable Plasma HIV RNA (n=117a) TFRC rs17091382 (A) Intronic Subcortical GM 3.23e-5 0.060
BMP6 rs7454156 (G) Intronic BG - Cr 7.65e-4 0.175
FXN rs2498434 (G) Intronic Sulcal CSF 5.13e-4 0.495
Minimal Comorbidity (n = 168) BMP6 rs752751 (T) Intronic Frontal GM - Cr 8.99e-4 0.477
Mild or Moderate Comorbidity (n = 75) CP rs4974389 (A) Intronic BG - Cho 3.52e-5 0.382
ACO2 rs9611598 (A) Intronic Subcortical GM 5.94e-5 0.023
Cerebellar GM 6.84e-4
BMP6 rs1358893 (T) Intronic Abnormal WM 7.02e-4 0.356
TF rs7633232 (C) Intronic Frontal GM - Cho 2.52e-4 0.014
Frontal GM - Cr 6.33e-4
Neurocognitively Normal (n = 167) SLC11A1 rs7576974 (T) Intronic/5’UTR Frontal GM - NAA 3.62e-5 0.066
BMP6 rs1107495 (G) Upstream 2 KB Frontal WM - Cr 2.19e-4 0.191
BMP6 rs9505293 (T) Intronic Cerebellar GM 9.10e-4 0.138
BMP6 rs7454156 (G) Intronic BG - MI 5.68e-4 0.175
BG - Cr 1.13e-3
BMP6 rs11960697 (A) Intronic Abnormal WM 7.46e-4 0.019
HFE rs1800562 (A) Missense Cerebellar GM 3.98e-4 0.033
HEPH rs7059116 (A) Intronic Frontal WM - MI 1.40e-4 0.111
ACO1 rs2026739 (G) Intronic Frontal WM - NAA 1.70e-4 0.339
Neurocognitively impaired (n = 76) ACO1 rs3780474 (G) Intronic Subcortical GM 2.81e-4 0.418
BMP6 rs9505293 (T) Intronic Cerebellar GM 4.92e-4 0.138
TF rs2718796 (G) Intronic Abnormal WM 1.03e-3 0.023
TF rs8177238 (G) Missense Frontal WM Cho 1.11e-3 0.023
TF rs8177241 (T) Intronic Frontal WM Cho 1.11e-3 0.027
FXN rs10126006 (A) Intronic Cortical GM 5.11e-4 0.346
Only p values for SNP associations that survived at least one level of multiple-testing correction (p < 0.00135 and p < 0.00006435) are shown, and those
SNPs meeting two levels of correction are bolded
Abbreviations: WM, white matter; GM, gray matter; NAA, N-acetylaspartate; Cr, Creatine; Cho, Choline; CSF, cerebrospinal fluid; GDS, Global Deficit
Score; MAF, minor allele frequency
aViral load measurements were not available for all participants
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HIV infection (McDermid et al. 2009). While stratified analy-
ses are not generally held to the same standard of multiple-
testing correction, this SNP in SLC11A1 also met a third level
of correction for the three hypotheses tests involved in stratified
analyses (significant p value threshold <2.14e-5). The Slc11A1
protein, along with ferroportin and the transferrin receptor
(encoded by SLC40A1 and TFRC, respectively), constitute ma-
jor proteins of the innate immune response (Johnson and
Wessling-Resnick 2012; Archer et al. 2015). SLC11A1 regu-
lates macrophage activation and has been associated with inci-
dent mycobacterial infection; this gene may also modulate neu-
roinflammation in HIV clade B infection and was linked to
HIV-related mortality among untreated persons living with
HIV in West Africa (Li et al. 2011; Yndart et al. 2015;
McDermid et al. 2009).
Additional analyses also revealed other statistically signifi-
cant SNPs that survived multiple-testing correction, in genes
with important roles in iron regulation and transport. SNP
rs13404407_C in ferroportin (SLC40A1 gene), despite being
present at low frequency (3%) in our study population, was
associated with a 2.5-fold higher volume of abnormal white
matter in aviremic individuals. Other SNPs, including
rs17091382_A in the transferrin receptor gene (TFRC) and
rs9611598_A in mitochondrial aconitase (ACO2 gene), showed
suggestive associations with less subcortical gray matter (ad-
justed odds ratio 0.90 in individuals with detectable plasma
virus, and odds ratio 0.73 among those with significant comor-
bidity, respectively). Finally, SNP rs4974389_A in CP was
associated with increased basal ganglia Choline, a marker of
inflammation and increased membrane turnover (Young et al.
2014). Importantly, like the SNP rs7576974_T in SLC11A1, we
note that the SNP in SLC40A1 (ferroportin), would also meet a
more stringent p value threshold that accounts for the 3 strata
analyzed (p < 2.14e-5). Nevertheless, results for this SNP must
be interpreted with caution, as only 3 individuals had variant
alleles at this locus in the aviremic subset. The magnitude of
individual SNP effects, beyond those of ferroportin and ACO2
genetic variants, was observed to be small.
Ferroportin is an extremely important molecule in iron me-
tabolism and innate immunity, serving as the portal for iron
entry from the gut into the bloodstream and for iron export from
macrophage-monocytes to metabolically active cells in the
brain, bone marrow and other tissues (Coffey and Ganz
2017). Like ferroportin, transferrin receptor 1, encoded by the
TFRC gene, is also widely expressed on most cells within the
CNS; transferrin receptor expression is essential to brain iron
uptake (Gebril et al. 2011). SNPs in these genes may therefore
disrupt the delicate balance between transferrin-mediated iron
uptake and ferroportin-related iron export, leading to mitochon-
drial dysfunction and cellular oxidative stress affecting the
white matter in particular. Aconitase is an iron-sulfur-cluster-
containing enzyme important for its participation in the tricar-
boxylic acid cycle, where it catalyzes the isomerization of
citrate; it is present in two forms, one localized to the cytoplasm
(cytoplasmic (c)-aconitase, encoded by ACO1) and one to lo-
calized to the mitochondrial matrix (mitochondrial (m)-
aconitase, encoded by ACO2) (Lushchak et al. 2014). Both
isoforms also function as biosensors of reactive oxygen species
and iron levels, with c-aconitase serving dual roles as an iron-
regulatory protein (IRP-1) that post-transcriptionally regulates
the synthesis of transferrin receptor and ferritin, depending on
ambient iron levels. Iron levels also appear to regulate the ex-
pression of aconitases; hence, these proteins serve to intimately
link iron metabolism to cellular energy requirements. Iron me-
tabolism is altered by HIV infection, and decreased serum cit-
rate levels, possibly reflecting altered aconitase activity, have
been documented in HIV+ persons compared to seronegative
controls (Pugliese et al. 2002). Furthermore, CSFmetabolomics
studies have documented an association between worsening
neurocognitive function in HIV infection and a shift to aerobic
glycolysis, accompanied by elevated CSF citrate and acetate
levels, in the absence of changes in plasma viral load
(Dickens et al. 2015). Decreases in the expression of c-
aconitase, ceruloplasmin, and possibly, ferroportin, have also
been suggested to lead to impairment of cellular iron export
and oxidative stress in Alzheimer’s disease (Guerreiro et al.
2015). M-aconitase activity in peripheral blood lymphocytes
is significantly reduced in patients with Alzheimer’s disease
and mild cognitive impairment (Mangialasche et al. 2015).
We previously identified effects of ACO1 SNP rs2026739 on
neuropathic pain severity in HIV+ CHARTER study partici-
pants (Kallianpur et al. 2014). This c-aconitase SNP and two
other mitochondrial iron transporters, frataxin and mitochondri-
al ferritin (encoded by FXN and FTMT, respectively) were also
associated with neuroimaging measures after the first level of
multiple-testing correction. Interestingly, frataxin is believed to
be important in shuttling iron between c-aconitase and IRP-1
(Lushchak et al. 2014).
Given that both HIV-associated neurocognitive disorder
and neuroimaging abnormalities develop and/or progress in
only a subset of HIV+ individuals (Harezlak et al. 2011;
Cysique et al. 2018; Heaton et al. 2010), there has been
longstanding debate as to the contribution of host genetic dif-
ferences. In this study of chronically HIV+ adults, we identi-
fied a total of 27 iron-regulatory genes harboring SNPs that
were significantly associated with neuroimaging measures in
multivariable models, either in the entire sample, or in a sub-
set. We found that SNP rs9611598_A in ACO2was associated
with higher basal ganglia Choline. The association of this SNP
in a gene involved in mitochondrial iron regulation and gly-
colytic metabolism with Choline, a marker that is elevated in
the brain during HIV infection (Harezlak et al. 2011), may
indicate pro-inflammatory cellular effects. Lastly, SNPs in at
least three genes were associated with changes in regional
brain volumes. Iron excess has been associated with brain
atrophy in other neurological and systemic disorders
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(Gazzina et al. 2016; Chai et al. 2015). Therefore, these SNPs
may modulate the risk of regional (e.g., subcortical) brain
atrophy, which is commonly observed in HIV+ individuals
and associated with NCI (Nir et al. 2014).
Iron homeostasis is essential for maintenance of mitochon-
drial function and energy production in the brain, as neural
tissues have extremely high metabolic demand, and iron is a
key component of the molecular complexes that constitute the
electron transport chain. Furthermore, by virtue of its ability to
readily accept and donate electrons, iron is a required cofactor
for a very large number of fundamental metabolic processes,
including synthesis of DNA, heme, monoamine neurotrans-
mitters, and myelin (Kallianpur et al. 2014; Patton et al. 2017;
Puig et al. 2017). However, iron that is not tightly protein-
bound is highly reactive and generates oxidative stress by
catalyzing free radical reactions. While studies in neonates
and adolescents have demonstrated lasting and often irrevers-
ible alterations of brain structure and cognitive ability follow-
ing iron deficiency early in life, the impact of both iron defi-
ciency and iron excess on brain integrity and function in adults
is considerably less well understood (Georgieff 2011; Belaidi
and Bush 2016). Iron present in excess or reactive forms is
also directly injurious, leading to neuronal death (Belaidi and
Bush 2016). Brain iron regulation is altered in several com-
mon neurodegenerative disorders, including Alzheimer’s dis-
ease, Parkinson’s disease, which involve abnormal concentra-
tions of iron in specific brain regions on neuroimaging studies
(Georgieff 2011; Pichler et al. 2013; Crespo et al. 2014). Brain
iron content has been associated with specific brain structures
on MRI in healthy and aging individuals, including the basal
ganglia and thalamus, and serum iron is associated with neu-
roimaging characteristics of these brain regions, as well as the
hippocampus (Jahanshad et al. 2012). Jahanshad et al.
(Jahanshad et al. 2012) found that in healthy young adults,
fractional anisotropy, a measure of brain white matter integrity
estimated from diffusion tensor imaging scans of the brain,
was associated with serum levels of the major iron transport
protein transferrin, measured years earlier during adolescence.
Lower transferrin levels were associated with higher frac-
tional anisotropy, suggesting greater brain integrity. Brain iron
normally increases with age, and both common and rare ge-
netic variants that affect iron transport are associated with
brain iron accumulation (Bettencourt et al. 2016). Age-
related white matter lesions in HIV-seronegative persons have
also been associated with increased ferric iron staining and a
pattern of decreased cellular iron influx, and increased export
of iron from cells was noted in messenger RNA expression
studies using quantitative PCR (Gebril et al. 2011). White
matter lesions, or abnormal white matter, are common among
HIV+ individuals and have been inconsistently associated
with neurocognitive deficits, even in aviremic persons
(Gongvatana et al. 2009; Alakkas et al. 2019). Abnormal
white matter increases with age and is more likely to be
associated with a history of severe immunosuppression, as
indicated by the CD4+ T cell count (Fennema-Notestine
et al. 2013). Synaptodendritic loss and microstructural dam-
age to white matter are also characteristic of HIV infection in
the current ART era (Kallianpur and Levine 2014).
Neuroimaging abnormalities may occur early in HIV infec-
tion, regardless of NCI, but few studies have documented
changes in brain iron distribution (Granziera et al. 2013).
The putamen may be more susceptible to these early HIV-
mediated changes (Wright et al. 2016). Granziera et al.
(Granziera et al. 2013) used more iron-sensitive imaging tech-
niques to show that loss of structural integrity could be dem-
onstrated in global white matter, cortical gray matter, thala-
mus, and basal ganglia in HIV+ persons with mild
neurocognitive disorders and undetectable HIV RNA in plas-
ma relative to healthy controls, and most of these alterations
were more pronounced than in unimpaired HIV+ persons. In
all HIV+ persons, T1 relaxation times were generally shorter
(and T2* longer) than in healthy controls, likely reflecting
lower iron content. The imaging measures used, however,
were not specific for iron. Older studies have suggested in-
creased brain iron deposition in the basal ganglia of HIV+
persons, as in older HIV-seronegative persons, particularly in
the globus pallidus and putamen (Miszkiel et al. 1997; Wright
et al. 2016). Soon after seroconversion, MRS metabolites also
are affected with changes that correlate with inflammation and
neuronal injury. HIV-related effects are generally observed in
subcortical (basal ganglia) and cortical (frontal and parietal)
gray matter as well as within the white matter, compared to
HIV-seronegative individuals. Furthermore, HIV+ persons
tend to have lower N-acetylaspartate and higher Choline and
Myo-inositol levels, with more severe effects reported in cog-
nitively impaired individuals. While ART ameliorates these
changes and can improve neurocognitive function, MRS me-
tabolite levels generally do not normalize.
We acknowledge the limitations of this study, despite several
strengths. Neuroimaging methods sensitive to iron status were
not performed: studies incorporating T2*, susceptibility-
weighted imaging, and other methods of iron-sensitive neuroim-
aging are underway. R2* relaxometry has been validated as a
means to quantify brain iron and should therefore also receive
consideration in future studies. The list of genes involved in iron
homeostasis is extremely large, and the 20 genes studied here
represent only a small fraction of polymorphic genes that may be
important in brain structure and metabolism. Genes such as
ACO1, SLC40A1, and HFE have previously been associated
with neurocognitive disorders and/or neurodegeneration
(Crespo et al. 2014; Jahanshad et al. 2012). HFE C187G geno-
types, which have been previously linked to other
neurocognitive disorders, were not available for these analyses.
Associations involving SNPs in TFRC, CP, and SLC11A1 were
statistically robust, but due to very small numbers of variant
alleles, findings for SNPs in SLC40A1 and ACO2 must be
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considered exploratory, requiring further study to determine if
the observed associations persist in other HIV+ and HIV sero-
negative populations. Due to the presence of 2 minor alleles in
only one individual at the SLC11A1 SNP locus, the impact of
allele dosage could not be assessed. Replication of our findings
in larger numbers of individuals with and without HIV, and
exploration of iron-related mechanisms of NCI, are therefore
needed. Furthermore, although we excluded severely confound-
ed cases and adjusted our analyses for a number of potentially
confounding variables, we cannot eliminate the possibility of
residual confounding; factors such as neuropsychiatric or sub-
stance abuse variables might also be associated with iron metab-
olism. Although the vast majority of substance use variables in
this cohort were previously shown to be unrelated to cognitive
function (Byrd et al. 2011), our findings may not generalize to
people with HIV infection who also have heavy or longstanding
substance use. Finally, the generalizability of these
neuroimaging-genetic findings to other HIV-seropositive co-
horts, and their link to HIV neuropathogenesis specifically, as
well as exploration of similar associations in HIV-seronegative
populations, remains to be determined in future studies.
Therefore, these results should be interpreted within the context
of HIV and may or may not be due to HIV infection.
Nevertheless, the multi-center design of this study, the diversity
of the study population, and the persistence of significant asso-
ciations after correcting for the number of evaluated genetic
haplotypes and neuroimaging measures, support the validity of
these findings and their generalizability to many people with
HIV.
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